环丙沙星治疗铜绿假单胞菌及其他耐药菌引起的感染。
Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.
作者信息
Eron L J, Harvey L, Hixon D L, Poretz D M
出版信息
Antimicrob Agents Chemother. 1985 Aug;28(2):308-10. doi: 10.1128/AAC.28.2.308.
Abstract
Ciprofloxacin was administered orally to 48 patients with 24 Pseudomonas aeruginosa infections and 13 other infections caused by cephalothin-resistant gram-negative bacilli. The types of infections treated included those of skin or skin structure, bone, urinary tract, and respiratory tract. In 83% of P. aeruginosa infections, a favorable clinical outcome occurred, compared with 85% for all infections. Failure to achieve a cure correlated with the emergence of resistant P. aeruginosa and Acinetobacter calcoaceticus strains in four instances and superinfection with Candida (two cases) and Streptococcus (two cases) species. Therapy was discontinued in three patients because of the development of nausea. Ciprofloxacin appears to be safe and effective in the therapy of infections caused by resistant gram-negative bacilli.
摘要
对48例患者口服环丙沙星，其中24例感染铜绿假单胞菌，13例感染由耐头孢菌素革兰阴性杆菌引起的其他感染。治疗的感染类型包括皮肤或皮肤结构、骨骼、泌尿道和呼吸道感染。在83%的铜绿假单胞菌感染中，临床结果良好，所有感染的这一比例为85%。未治愈与4例出现耐药铜绿假单胞菌和醋酸钙不动杆菌菌株以及念珠菌（2例）和链球菌（2例）二重感染有关。3例患者因出现恶心而停药。环丙沙星在治疗由耐药革兰阴性杆菌引起的感染方面似乎是安全有效的。
相似文献
1
Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.环丙沙星治疗铜绿假单胞菌及其他耐药菌引起的感染。
Antimicrob Agents Chemother. 1985 Aug;28(2):308-10. doi: 10.1128/AAC.28.2.308.
2
Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.口服环丙沙星治疗铜绿假单胞菌感染
Lancet. 1986 Apr 12;1(8485):819-22. doi: 10.1016/s0140-6736(86)90937-2.
3
Ciprofloxacin in the treatment of urinary tract infections caused by Pseudomonas aeruginosa and multiresistant bacteria.
Eur J Clin Microbiol. 1986 Apr;5(2):255-7. doi: 10.1007/BF02014004.
4
Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis.环丙沙星治疗慢性支气管炎急性加重期
Eur J Clin Microbiol. 1986 Apr;5(2):226-31. doi: 10.1007/BF02013995.
5
Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria.环丙沙星治疗由耐庆大霉素革兰氏阴性菌引起的感染。
Eur J Clin Microbiol. 1986 Apr;5(2):248-51. doi: 10.1007/BF02014001.
6
Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.环丙沙星治疗铜绿假单胞菌感染的评估。
Eur J Clin Microbiol. 1986 Apr;5(2):232-5. doi: 10.1007/BF02013996.
7
Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
Eur J Clin Microbiol. 1986 Apr;5(2):236-40. doi: 10.1007/BF02013997.
8
9
Oral treatment of Pseudomonas-induced urinary tract infections with ciprofloxacin.
Chemotherapy. 1986;32(1):83-7. doi: 10.1159/000238392.
10
Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other than Pseudomonas aeruginosa.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:179-85. doi: 10.1093/jac/18.supplement_d.179.
引用本文的文献
1
Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model.环丙沙星通过 Calu-3 气道上皮细胞模型被主动转运至支气管肺上皮细胞中。
Antimicrob Agents Chemother. 2013 Jun;57(6):2535-40. doi: 10.1128/AAC.00306-13. Epub 2013 Mar 18.
2
Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection.在体外感染模型中，静脉注射环丙沙星针对铜绿假单胞菌和金黄色葡萄球菌的剂量范围及分割剂量研究
Antimicrob Agents Chemother. 1993 Sep;37(9):1756-63. doi: 10.1128/AAC.37.9.1756.
3
nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa.铜绿假单胞菌临床分离株中的 nfxC 型喹诺酮耐药性
Antimicrob Agents Chemother. 1995 Mar;39(3):790-2. doi: 10.1128/AAC.39.3.790.
4
Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa.环丙沙星和培氟沙星单独使用或与磷霉素联合使用在多药敏感和耐药铜绿假单胞菌引起的实验性心内膜炎中的比较疗效。
Antimicrob Agents Chemother. 1995 Feb;39(2):496-9. doi: 10.1128/AAC.39.2.496.
5
Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin.接受环丙沙星单独治疗或与万古霉素联合治疗的志愿者血清的杀菌活性和杀菌率。
Antimicrob Agents Chemother. 1986 Dec;30(6):892-5. doi: 10.1128/AAC.30.6.892.
6
Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity.儿童使用萘啶酸：软骨毒性的回顾性配对对照研究
Infection. 1987 May-Jun;15(3):165-8. doi: 10.1007/BF01646040.
7
Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection.软组织感染患者中左氧氟沙星的临床疗效及组织水平
Antimicrob Agents Chemother. 1987 May;31(5):805-7. doi: 10.1128/AAC.31.5.805.
8
Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.口服环丙沙星治疗骨、关节和软组织感染。
Antimicrob Agents Chemother. 1987 Feb;31(2):151-5. doi: 10.1128/AAC.31.2.151.
9
Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections.口服环丙沙星治疗严重尿路感染的疗效与安全性。
Antimicrob Agents Chemother. 1987 Feb;31(2):148-50. doi: 10.1128/AAC.31.2.148.
10
Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections.环丙沙星与亚胺培南-西司他丁治疗严重临床感染的前瞻性随机对照研究。
Antimicrob Agents Chemother. 1987 Oct;31(10):1491-6. doi: 10.1128/AAC.31.10.1491.
本文引用的文献
1
Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.羟羧氧酰胺菌素治疗对头孢噻吩耐药菌引起的感染：血清抑制活性对治疗期间临床反应及抗生素耐药性获得的影响
Antimicrob Agents Chemother. 1981 Sep;20(3):351-5. doi: 10.1128/AAC.20.3.351.
2
Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse.哌拉西林治疗伴有铜绿假单胞菌耐药获得及临床复发情况的临床试验
Antimicrob Agents Chemother. 1980 Jul;18(1):167-70. doi: 10.1128/AAC.18.1.167.
3
A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam.亚胺培南/西司他丁与拉氧头孢比较疗效、安全性及耐受性的多中心随机研究
Eur J Clin Microbiol. 1984 Oct;3(5):478-87. doi: 10.1007/BF02017380.
4
Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.头孢他啶在严重感染治疗中的应用，包括由多重耐药菌引起的感染。
Antimicrob Agents Chemother. 1983 Aug;24(2):176-80. doi: 10.1128/AAC.24.2.176.
5
In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.诺氟沙星和环丙沙星对结核分枝杆菌、鸟分枝杆菌复合体、龟分枝杆菌、偶然分枝杆菌和堪萨斯分枝杆菌的体外活性。
Antimicrob Agents Chemother. 1984 Jul;26(1):94-6. doi: 10.1128/AAC.26.1.94.
6
Ceftazidime in patients with Pseudomonas infections.
J Antimicrob Chemother. 1983 Jul;12 Suppl A:161-9. doi: 10.1093/jac/12.suppl_a.161.
7
Piperacillin therapy for Pseudomonas infections.
South Med J. 1983 Jul;76(7):859-62. doi: 10.1097/00007611-198307000-00010.
8
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.新型喹啉衍生物Bay 09867与其他抗菌药物的体外活性比较。
Antimicrob Agents Chemother. 1983 Apr;23(4):559-64. doi: 10.1128/AAC.23.4.559.
9
Clinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infections.羟羧氧酰胺菌素治疗铜绿假单胞菌感染和非铜绿假单胞菌感染的临床经验。
Antimicrob Agents Chemother. 1982 Apr;21(4):568-74. doi: 10.1128/AAC.21.4.568.
10
Tobramycin sulfate: a summary of worldwide experience from clinical trials.
J Infect Dis. 1976 Aug;134 Suppl:S219-34. doi: 10.1093/infdis/134.supplement_1.s219.
Zotero 插件